The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
15 08 2023
Historique:
received: 21 02 2023
revised: 20 04 2023
accepted: 02 06 2023
medline: 16 8 2023
pubmed: 8 6 2023
entrez: 8 6 2023
Statut: ppublish

Résumé

Systemic targeted therapy in prostate cancer is primarily focused on ablating androgen signaling. Androgen deprivation therapy and second-generation androgen receptor (AR)-targeted therapy selectively favor the development of treatment-resistant subtypes of metastatic castration-resistant prostate cancer (mCRPC), defined by AR and neuroendocrine (NE) markers. Molecular drivers of double-negative (AR-/NE-) mCRPC are poorly defined. In this study, we comprehensively characterized treatment-emergent mCRPC by integrating matched RNA sequencing, whole-genome sequencing, and whole-genome bisulfite sequencing from 210 tumors. AR-/NE- tumors were clinically and molecularly distinct from other mCRPC subtypes, with the shortest survival, amplification of the chromatin remodeler CHD7, and PTEN loss. Methylation changes in CHD7 candidate enhancers were linked to elevated CHD7 expression in AR-/NE+ tumors. Genome-wide methylation analysis nominated Krüppel-like factor 5 (KLF5) as a driver of the AR-/NE- phenotype, and KLF5 activity was linked to RB1 loss. These observations reveal the aggressiveness of AR-/NE- mCRPC and could facilitate the identification of therapeutic targets in this highly aggressive disease. Comprehensive characterization of the five subtypes of metastatic castration-resistant prostate cancer identified transcription factors that drive each subtype and showed that the double-negative subtype has the worst prognosis.

Identifiants

pubmed: 37289025
pii: 727214
doi: 10.1158/0008-5472.CAN-23-0593
pmc: PMC10425725
doi:

Substances chimiques

Receptors, Androgen 0
Androgen Antagonists 0
Androgens 0

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

2763-2774

Subventions

Organisme : NCI NIH HHS
ID : P50 CA186786
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA227025
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA230516
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA251245
Pays : United States

Informations de copyright

©2023 The Authors; Published by the American Association for Cancer Research.

Références

Innovation (Camb). 2021 Jul 01;2(3):100141
pubmed: 34557778
Oncogene. 2020 Feb;39(6):1335-1346
pubmed: 31636385
Nat Med. 2013 Aug;19(8):1023-9
pubmed: 23817021
Cancer Cell. 2017 Oct 9;32(4):474-489.e6
pubmed: 29017058
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
Cancer Res. 2022 Nov 2;82(21):3888-3902
pubmed: 36251389
Brief Funct Genomics. 2016 Nov;15(6):443-453
pubmed: 27416614
J Clin Oncol. 2013 May 10;31(14):1748-57
pubmed: 23569316
N Engl J Med. 1995 May 25;332(21):1393-8
pubmed: 7723794
J Exp Clin Cancer Res. 2010 Sep 01;29:119
pubmed: 20809941
Cell. 2018 Jul 26;174(3):758-769.e9
pubmed: 30033370
Nature. 2017 Jan 19;541(7637):359-364
pubmed: 28068672
Bioinformatics. 2011 Apr 1;27(7):1017-8
pubmed: 21330290
BMC Cancer. 2012 Jun 15;12:248
pubmed: 22703285
Nat Commun. 2022 May 13;13(1):2559
pubmed: 35562350
Nature. 2020 Aug;584(7820):244-251
pubmed: 32728217
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Science. 2017 Jan 6;355(6320):78-83
pubmed: 28059767
J Clin Oncol. 2018 Aug 20;36(24):2492-2503
pubmed: 29985747
J Pathol. 2018 Dec;246(4):497-507
pubmed: 30101462
Genome Biol. 2014;15(12):550
pubmed: 25516281
J Clin Invest. 2019 Jul 30;129(10):4492-4505
pubmed: 31361600
Nat Rev Cancer. 2015 Dec;15(12):701-11
pubmed: 26563462
Oncotarget. 2016 Aug 16;7(33):53074-53101
pubmed: 27447975
EBioMedicine. 2017 Apr;18:83-93
pubmed: 28412251
Nat Genet. 2020 Aug;52(8):778-789
pubmed: 32661416
Nat Genet. 2003 Jun;34(2):187-92
pubmed: 12740577
Cancer Cell. 2018 Dec 10;34(6):996-1011.e8
pubmed: 30537516
Nature. 2010 Feb 18;463(7283):958-62
pubmed: 20130577
Genome Biol. 2013 Mar 12;14(3):R21
pubmed: 23497655
Cell Rep. 2015 Aug 18;12(7):1184-95
pubmed: 26257180
Genome Med. 2017 Apr 18;9(1):35
pubmed: 28420412
Nat Commun. 2021 Mar 17;12(1):1714
pubmed: 33731701
J Clin Invest. 2020 Aug 3;130(8):3987-4005
pubmed: 32343676
Nat Rev Genet. 2014 Apr;15(4):272-86
pubmed: 24614317
Cancer Cell. 2011 May 17;19(5):575-86
pubmed: 21575859
Science. 2017 Jan 6;355(6320):84-88
pubmed: 28059768
Nat Genet. 2011 Jun;43(6):607-11
pubmed: 21532573
Sci Rep. 2019 Mar 8;9(1):3952
pubmed: 30850678
Nature. 2022 Aug;608(7921):199-208
pubmed: 35859180
Nature. 2019 Nov;575(7781):210-216
pubmed: 31645765
Nat Commun. 2022 Sep 15;13(1):5345
pubmed: 36109521
Cancer Discov. 2011 Nov;1(6):466-8
pubmed: 22586648
Cancer Cell. 2019 Aug 12;36(2):139-155.e10
pubmed: 31327655
J Clin Oncol. 2015 Jan 20;33(3):244-50
pubmed: 25366685
EMBO J. 1991 Sep;10(9):2559-67
pubmed: 1714382
Eur Urol. 2015 Apr;67(4):795-802
pubmed: 25454616
Mol Cell. 2010 May 28;38(4):576-89
pubmed: 20513432
Nat Med. 2016 Mar;22(3):298-305
pubmed: 26855148
PLoS Genet. 2010 Jul 15;6(7):e1001023
pubmed: 20657823
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Nat Genet. 2018 May;50(5):645-651
pubmed: 29610475
Mol Cancer Res. 2019 Jun;17(6):1235-1240
pubmed: 30918106
Life Sci Alliance. 2019 Nov 15;2(6):
pubmed: 31732695
Sci Rep. 2019 Jun 27;9(1):9354
pubmed: 31249361
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Semin Cancer Biol. 2020 Dec;67(Pt 1):122-153
pubmed: 30914279
Front Cell Neurosci. 2017 Mar 29;11:89
pubmed: 28424591
Nat Commun. 2022 Apr 27;13(1):2282
pubmed: 35477723
Nucleic Acids Res. 2015 Dec 2;43(21):e141
pubmed: 26184873
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Nat Commun. 2021 Sep 6;12(1):5307
pubmed: 34489465
Sci Rep. 2020 Oct 15;10(1):17445
pubmed: 33060836
N Engl J Med. 2015 Oct 29;373(18):1697-708
pubmed: 26510020
Nat Commun. 2021 Nov 4;12(1):6377
pubmed: 34737261
Nat Commun. 2018 Nov 21;9(1):4900
pubmed: 30464211
Cell. 2018 Feb 8;172(4):650-665
pubmed: 29425488
Nucleic Acids Res. 2022 Jan 7;50(D1):D165-D173
pubmed: 34850907
Cell. 1987 Nov 6;51(3):435-43
pubmed: 2889531
Clin Cancer Res. 2016 Mar 15;22(6):1520-30
pubmed: 26546618

Auteurs

Arian Lundberg (A)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Department of Radiation Oncology, University of California San Francisco, San Francisco, California.

Meng Zhang (M)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Department of Radiation Oncology, University of California San Francisco, San Francisco, California.

Rahul Aggarwal (R)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.

Haolong Li (H)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Department of Radiation Oncology, University of California San Francisco, San Francisco, California.

Li Zhang (L)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.

Adam Foye (A)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Department of Radiation Oncology, University of California San Francisco, San Francisco, California.

Martin Sjöström (M)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Department of Radiation Oncology, University of California San Francisco, San Francisco, California.

Jonathan Chou (J)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.

Kevin Chang (K)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.

Thaidy Moreno-Rodriguez (T)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Department of Urology, University of California San Francisco, San Francisco, California.

Raunak Shrestha (R)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Department of Radiation Oncology, University of California San Francisco, San Francisco, California.

Avi Baskin (A)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Department of Radiation Oncology, University of California San Francisco, San Francisco, California.

Xiaolin Zhu (X)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.

Alana S Weinstein (AS)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Department of Radiation Oncology, University of California San Francisco, San Francisco, California.

Noah Younger (N)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.

Joshi J Alumkal (JJ)

Division of Hematology and Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.

Tomasz M Beer (TM)

Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon.

Kim N Chi (KN)

Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.

Christopher P Evans (CP)

Comprehensive Cancer Center, University of California Davis, Sacramento, California.
Department of Urologic Surgery, University of California Davis, Sacramento, California.

Martin Gleave (M)

Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.

Primo N Lara (PN)

Comprehensive Cancer Center, University of California Davis, Sacramento, California.
Division of Hematology Oncology, Department of Internal Medicine, University of California Davis, Sacramento, California.

Rob E Reiter (RE)

Departments of Medicine, Hematology/Oncology and Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California.

Matthew B Rettig (MB)

Departments of Medicine, Hematology/Oncology and Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California.
VA Greater Los Angeles Healthcare System, Los Angeles, California.

Owen N Witte (ON)

Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.

Alexander W Wyatt (AW)

Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia, Canada.

Felix Y Feng (FY)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Department of Radiation Oncology, University of California San Francisco, San Francisco, California.
Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.
Department of Urology, University of California San Francisco, San Francisco, California.

Eric J Small (EJ)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.

David A Quigley (DA)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Department of Urology, University of California San Francisco, San Francisco, California.
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH